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Dry eye is a common clinical condition diagnosed by cumulative evidence of symptoms and signs. Many new
treatments in dry eye are either expensive, invasive, have potential for side effects, or are not easily accessible. In
severe dry eye, the ideal modality of treatment to begin with is often not clear as specific molecular disturbances
are not evident from just examination of clinical manifestations. Assessing the effects of ongoing treatment is not
straight forward since there is lack of agreement between clinical signs and symptoms. There is a need to have
more objective methods of selecting treatment for dry eye and monitoring the effect of treatment.
Recently, there are many new technologies applied to the discovery of tear biomarkers, for e.g., mass spectrometry
based proteomics techniques and multiplex assays such as the bead-based sandwich indirect immunofluorescent
assays. Tear proteins assays have even been made available as point-of-care devices. This review focuses on the
evidence for the involvements of tear proteins in dry eye, possible changes in tear concentrations with therapy and
the strength of evidence regarding dry eye pathology. Much remains to be done in terms of developing office-based
assays and ascertaining their reliability, but current evidence suggests that tear proteins have a role in the clinical
practice of dry eye.
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Diagnosis of dry eye
According to the International Dry Eye Workshop, “dry
eye is a multifactorial disease of the tear and ocular sur-
face that results in symptoms of discomfort, visual dis-
turbance, and tear instability with potential damage to
the ocular surface. It is accompanied by increased osmo-
larity of the tear and inflammation of the ocular surface”
[1]. Simply put, dry eye is a complex multifactorial dis-
order affected by pathological processes such as lacrimal
gland inflammation [2], meibomian gland dysfunction
[3], and tear hyperosmolarity [1].
The signs and symptoms of dry eye disease do not al-
ways correlate well even though both are important in
the diagnosis and management of dry eye. There are a
number of tests used in clinical practice for the diagno-
sis of dry eye including the traditional Schirmer test, tear* Correspondence: Louis.tong.h.t@snec.com.sg
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article, unless otherwise stated.break up time, rose bengal staining and the more ad-
vanced technologies like the tear osmolarity, meibogra-
phy and tear film interferometry. Unfortunately the
available diagnostic tests often do not correlate reliably
with severity of the patient’s symptoms [4].
Recently, a panel of tear proteins has been found,
which may be specific and sensitive for the detection of
dry eye [5]. A similar panel has been advocated for the
diagnosis of primary Sjogren syndrome [6]. The import-
ance of this discovery lies in the fact that most of the
diagnostic tests need to be used in combination to reli-
ably diagnose dry eye. These tear proteins may thus
prove invaluable to the practicing ophthalmologist. Dis-
ease specific signatures of tear proteins may demonstrate
underlying disease pathways, and about 4-5% of proteins
may be deranged in dry eye [7]. Since tear fluid has various
components secreted by different glands, the composition
of tears reflects the health of different components of the
ocular surface [8]. For some time now, the level of
secretory IgA in the tears was used as a measure of lacri-
mal function, and could be used as a marker of ocular sur-
face inflammation. It fluctuates diurnally in normal people,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to be reduced in dry eye compared to controls [9].
What is the cause of increased cytokines in dry eye? It
is hypothesised that in the dry eye, the increased con-
centration of cytokines is not due to evaporation, but ra-
ther attributed to the upregulation of inflammatory
genes in the conjunctival epithelium. This results in the
increased production of inflammatory cytokines in tears
[10]. The increase in tear cytokines was correlated to de-
rangements in tear function tests such as osmolarity
[11], suggesting that they reflect the underlying disease
mechanisms.
In fact when a neural network was used to examine
the tear proteins of dry eye patients and normal partici-
pants, multivariate analysis was able to discriminate the
proteins from these two groups [12]. Specific protein de-
rangements in dry eye patients further point to clinical
subgroups of patients such as meibomian gland dysfunc-
tion [13], preservative induced dry eye in glaucoma pa-
tients [14], aqueous deficient dry eye [11], or diabetes [15].
Differential diagnosis
The symptoms of dry eye can sometimes be non-specific.
Dry eye symptoms like chronic irritation, tearing and eye
redness may be mimicked by other conditions like allergic
conjunctivitis [16]. Therefore, an objective test would be
useful to distinguish dry eye from its mimickers. In fact, a
decrease in tear break up time, which is a hallmark of cer-
tain types of dry eye disease, when present in isolation
without the other signs of dry eye, may be a feature of al-
lergic conjunctivitis [17], thus suggesting that it is unreli-
able to diagnose dry eye with only one single clinical test.
In patients with chronic conjunctivitis, an elevated tear
IgE may be a clue to underlying allergic conjunctivitis
[18]. Cytokines in dry eye involve mainly Th1 and Th17
subsets whereas in allergic eye disease, T helper type 2-
related mechanisms are involved in the sensitization
phase, but both T helper type 1 and type 2 cytokines are
overexpressed in the active disease, contributing to the de-
velopment of ocular inflammation [19].
Other conditions we need to differentiate from idio-
pathic dry eye are those in which dry eye is associated
with an underlying systemic cause. It may be possible to
have a higher index of suspicion for a systemic cause of
dry eye based on the levels of specific tear glycoproteins
in addition to relevant history and clinical findings. For
example, conditions such as pemphigoid may affect the
glycoproteins differently from age-related dry eye [20].
It is important to assess the suitability of a tear protein
as a biomarker before analysis. In this article we con-
sider a tear protein to be potentially suitable as a clinical
biomarker if it fulfils the following three criteria in the
literature available: Firstly, the tear proteins which have
been studied in dry eye disease in humans and found tobe consistently deranged with a clearly defined normal
range may be considered to be more relevant for clinical
use. Secondly, the tear proteins that have been shown to
change with the severity of dry eye, especially in longitu-
dinal studies or trials are given importance. Lastly, there
should be some link between dry eye pathology and the
function of the measured tear protein. Such a link can
be provided by relevant in vivo experiments in animals
or an intervention that produced a known biological ef-
fect such as inflammation in humans.
The factors which we used to assess the suitability for
use as clinical markers are shown in Table 1. For simpli-
city, we only show one member of each class or type of
protein (except the class called ‘lacrimal proteins’). These
interpretations are based on subjective evaluation of the
current evidence on the tear protein studies presented in
this review, and may need to be revised when new studies
are published (Table 1). There is no published review
which focused on these 3 criteria for determining the
clinical relevance of the tear proteins in dry eye, therefore,
we aim to provide a concise guide to enumerate these
factors for the common tear proteins.
Review
Tear proteins
Available technologies and use in dry eye
Traditional separation of tear proteins was performed by
electrophoresis [77], and identification and quantifica-
tion by the enzyme linked immunosorbent (ELISA)
method [78], but the recent advances in analytical tech-
nologies have provided ocular surface scientists with a
host of other techniques for examination of tear pro-
teins. The nano-scale sensitivity of some recent tech-
nologies enable the detection of proteins in tears from
individuals rather than pooled samples [79,80]. Some of
the techniques described below can be used for relative
or even absolute quantification if standards of known
concentration are also available for calibration. One of
the techniques of separating proteins rely on high perform-
ance liquid chromatography [81], or nano-electrospray li-
quid chromatography [82], where the size and charge of
proteins provide the basis for their separation. The various
techniques available are isobaric tagging using relative and
absolute quantification (iTRAQ) technology, and the matrix
assisted laser desorption ionisation (MALDI) time of flight
(TOF) technique with mass spectrometry [83]. A variant
of this technique is the surface-enhanced laser desorption/
ionization (SELDI) TOF which can also be coupled with
mass spectrometry [65].
Two dimensional (2D) separation of tear proteins based
on mass/charge followed by dye staining have also been
performed for separation and later identification of tear
proteins [84]. In diabetic people, tear proteins have been
evaluated using the 2D electrophoresis technology [85].
Table 1 Evidence for assessing the suitability of tear proteins for clinical use
















in dry eye pathology
known?
Lacrimal protein Lactoferrin ++++ [21-25] +++ [26,27] + [28] ++ [29]
Protease MMP-9 +++ [30-32] +++ [11] +++ [33] +++ [34-42]
Lacrimal protein Lysozyme ++ [21,43-45] + [43] 0 0
Mucins MUC5AC +++ [46,47] + [48] 0 ++ [49,50]
Lipid binding protein Lipocalin ++ [45,51] + [52] ++ [52] + [53-55]
Interleukines IL-6 +++ [10,31,56,57] + [58] ++ [58] + [59-61]
Chemokine IL-8 ++ [10,57,62,63] ++ [62] 0 ++ [61,64]
Keratinisation-related S100A8/9 +++ [5,13,14,65] +++ [5,13] 0 + [66,67]
Epithelial health EGF ++ [57,64,68] + [69] 0 ++ [70]
Neurotrophic health NGF +++ [71,72] ++ [71,73,74] ++ [73,74] ++ [75,76]
++++ strong evidence.
+++ good evidence.
++ modest evidence, some uncertainties about implication.
+ some evidence but studies may have conflicting results.
0 no clear evidence.
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sulphate (SDS) polyacrylamide gel electrophoresis (PAGE),
an older technology, was able to detect glycation at spe-
cific residues of tear proteins such as lactoferrin and im-
munoglobulins [86].
Protein arrays have been used to detect proteins from
tears of Sjogren syndrome patients [87]. This involves
the binding of tear proteins to a predetermined set of
antibodies arranged in a fixed arrangement in a station-
ary platform. In some unique scenarios, for example, to
compare the types of immunoglobulins in tears, a more
traditional assay such as the Western or immunoblot
assay can be performed [88]. For office-based diagnosis,
tear proteins can be separated in a very short time using
a commercially available equipment, the Agilent Bioana-
lyser 2100, and analysed using the microfluidic based
lab-on-chip technology [89]. For the analysis of a dozen
or more cytokines and chemokines in a few microliter of
tears, it seems the best technology is the multiplex bead-
based immunofluorescent sandwich assay, and the sensi-
tivity for detection of some cytokines are in the order of
several picogram/milliliter concentrations, surpassing
even the minimum detection limits of mass spectrom-
etry based methods [90].
Limitations
There are some pitfalls to tear protein analysis such as:
differences in methods of tear collection which can give
different results [91]. Tear collection may be done using
Schirmer strips, capillary tubes, or even a special minis-
ponge [92]. A key consideration is the comfort and min-
imal stimulation of the patient during tear collection,avoiding reflex tearing, since reflex tears likely have dif-
ferent tear protein levels from basal tears. Tear concen-
trations of interleukin (IL)-1 alpha, precursor IL-1 beta,
and IL-1 receptor antagonist (RA) may be altered in dry
eye in the basal but not the reflex tear [30]. The Schirmer
test method has been shown to be reliable for the collec-
tion of tears for analysis of multiple cytokines [93], and
such evaluation would be necessary as a prerequisite for
new methods of tear collection proposed in the future.
The techniques of iTRAQ, MALDI TOF, SELDI TOF
and 2D electrophoresis have shown to be useful for
evaluation of tear proteins in a research setting but are
unlikely to be used in clinics.
In summary, there is no universal methodology for
handling or analysing tear proteins that is applicable to
all clinics. Clinicians should consider the advantages and
pitfalls of various methods should they want to apply
these in their practice. Once applied, the same method
should be continued for subsequent encounters and
other patients.
A ‘traditional’ marker: Lysozyme
This protein, also known as muramidase or N-acetylmura-
mide glycanhydrolase is a glycoside hydrolase, which are
enzymes that damage bacterial cell walls by catalyzing the
hydrolysis of 1,4-beta-linkages between N-acetylmuramic
acid and N-acetyl-D-glucosamine residues in a peptidogly-
can. Lysozymes are abundant in a number of secretions,
such as tears, saliva, human milk, and mucus [94]. Lyso-
zyme is probably the earliest tear protein studied in con-
junction with dry eye, and the level of tear lysozyme was
noted to increase with age till 40 and decrease thereafter
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with chronic medication induced dry eye [44]. In a large
study with 262 patients (78 patients with Sjogren syn-
drome), the concentrations of the lysozyme and lactoferrin
protein in tear samples in Sjogren syndrome were deter-
mined [21]. It was found that lysozyme was decreased in
idiopathic dry eye and Sjogren syndrome compared to
controls [43]. However, a later study showed that lysozyme
concentration did not differ between non-Sjogren dry eye,
Sjogren syndrome or normal controls [45]. Researchers
also found the single protein lysozyme test to be insuf-
ficient for the diagnosis of dry eye [95]. Nevertheless,
lysozyme levels may be useful in specific contexts, for ex-
ample, to check for adverse effects of beta-adrenergic re-
ceptor blocking drugs such as Practalol, which reduced
tear lysozyme levels [96] or to detect dry eye from specific
occupational exposures in coal mining [97]. With so many
existing and emerging technologies, it may be worthwhile
to take a fresh look at the utility of lysozyme.
Lactoferrin revisited
Lactoferrin, also known as lactotransferrin, is a non-
haem iron-binding protein of the transferrin family. It is
a globular glycoprotein with a molecular mass of about
80 kDa that is widely represented in various secretory
fluids, such as milk, saliva, tears and nasal secretions.
Lactoferrin is one of the components of the immune
system of the body. It has antimicrobial activity, is anti-
viral, antiparasitic, catalytic, immunomodulatory and anti-
inflammatory [98].
It was found to be negatively correlated to Rose Bengal
staining, indicating that reduced lactoferrin was a marker
of ocular surface damage [26]. However, in evaporative
dry eye in the absence of epithelial defects, tear lactoferrin
was also found to be reduced [99]. In chronic hepatitis C
patients, the cotton thread test of tear secretion was
weakly correlated (r = 0.35) to the tear lactoferrin levels
[27], indicating that these patients having significantly
lower tear lactoferrin levels than control participants. The
use of tear lactoferrin has been advocated for the diagnosis
of primary Sjogren’s syndrome, where the test had a speci-
ficity of 95% and a sensitivity of 72% [22]. These values
were somewhat superior to using only the Schirmer I test
for detection of this disease [22]. Researchers have sug-
gested a cut-off value of 1.1 mg/mL for tear lactoferrin so
that the assay has optimal accuracy for the diagnosis of
dry eye [23]. Using this threshold, the test was able to de-
tect dry eye with a sensitivity 79.4% and specificity of
78.3% [24]. Using a convenient commercial lactoplate
assay, the tear lactoferrin was measured in dry eye patients
and was decreased relative to controls [25].
However, it has been found that lactoferrin changes ei-
ther do not appear early enough for diagnosis of mild to
moderate dry eye or that some cases of dry eye did nothave the lacrimal dysfunction that this assay tested for
[100]. In any case, treatment of dry eye with punctal oc-
clusion was associated with increased tear lactoferrin
levels, suggesting that tear levels of this protein may be a
measure of tear turnover [28]. Recently a TearScan™
Lactoferrin Diagnostic Test Kit was made available com-
mercially (Advanced Tear Diagnostics, Raleigh, NC).
This device provides quantitative point-of-care tear con-
centration of lactoferrin.
S-100A proteins
The S-100A protein is a family of low molecular weight
proteins characterized by two calcium binding sites of
the helix-loop-helix conformation and at least 21 differ-
ent types of S100 proteins are known. It is normally
present in cells derived from the neural crest (Schwann
cells, melanocytes and glial cells), chondrocytes, adipo-
cytes, myoepithelial cells, macrophages, Langerhans cells,
dendritic cells, and keratinocytes. S100 proteins are in-
volved in the regulation of protein phosphorylation, tran-
scription factors, calcium homeostasis, the dynamics of
cytoskeleton constituents, enzyme activities, cell growth
and differentiation, and the inflammatory response [101].
The S100 A8 and A9 proteins have been known to be
pro-inflammatory [66]. In a study using the isobaric tag-
ging for relative and absolute quantification (iTRAQ)
technology, we found the S100A8 and S100A9 proteins
were among a panel of 6 upregulated proteins found in
the tear of dry eye patients [5]. The average ratio of
S100A8 and S100A9 in dry eye versus control subjects
was 1.82 (SD 1.41) and 1.92 (SD 1.48) respectively. In
another study using a different SELDI-TOF technique,
over-expression of S100A8 has also been reported [65].
Mucin and related molecules
The mucins (MUC) are a family of high molecular weight,
hydrophilic, heavily glycosylated proteins, produced by
epithelial tissues. The tear film on the ocular surface
epithelia is maintained by the mucins on its surface as well
as by membrane-associated mucins in the apical surface of
the cell. They are secreted by goblet cells or other
secretory cells and have a characteristic ability to form gels
with the exception of the monomeric MUC7, hence they
have various functions from lubrication to cell signalling
to form chemical barriers. MUCs 1, 3A, 3B, 4, 12, 13, 15,
16, 17 and 20 are membrane associated and MUCs 2,
5 AC, 5B, 6, 7 and 19 have been classified as secreted
mucins [102].
Using Schirmer strip samples, mean MUC5AC content
in tears was found to be lower in the dry eye patients
than in the age- and gender-matched healthy individuals
[46]. The levels of certain mucin molecules were associ-
ated with certain ocular surface states. For example, tear
MUC5AC was reduced in symptomatic contact lens
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temporal lid parallel conjunctival folds (conjunctivocha-
lasis) and lid wiper epitheliopathy [48]. The levels of
mucins are not always depressed in dry eye. Sjogren syn-
drome patients exhibited increased soluble MUC16 in
the tear compared to controls [47]. The membrane-
associated MUC16 and the mucin-associated T-antigen
carbohydrate were associated with ocular surface epithe-
lial protection [103].
Understanding of tear mucin regulation may produce
insight into the mechanism of at least some types of dry
eye [49]. Phospholipid transfer protein, a protein that in-
teracts with mucins, may also be relevant to the dry eye
mechanism [104], but this has not been studied well
enough to be used for clinical purposes. Since the regu-
lation of mucin affects dry eye pathologic mechanisms,
it gives greater credibility to the use of mucins as a
marker for this disease.
Proteases
Protease refers to a group of enzymes whose catalytic
function is to hydrolyse (breakdown) peptide bonds of
proteins. They are also called proteolytic enzymes or
proteinases. Proteases differ in their ability to hydrolyse
various peptide bonds. Matrix metalloproteinases (MMPs)
are a class of proteases belonging to the metzincin super-
family characterised by zinc cofactors, and they are the
most important proteases found in tears [105,106].
These enzymes degrade extracellular matrix proteins,
but can also process certain bioactive molecules. They
are also associated with cleavage of cell surface recep-
tors, the release of apoptotic ligands (like the FAS lig-
and), and chemokine/cytokine in/activation. MMPs also
play a major role cell proliferation, migration (adhesion/
dispersion), differentiation, apoptosis, and host defense
[106]. MMP-9, also known as 92 kDa type IV collage-
nase or gelatinase B, can be involved in the degradation
of collagen IV present in the basement membrane and
extracellular matrix.
In rosacea-associated meibomian gland disease or
Sjogren’s syndrome, the tear activity of MMP9 was raised
compared to controls [30]. In another study, pro-MMP-9
levels were found to be significantly elevated in various
ocular surface diseases: blepharitis (p = 0.013), allergic eye
disease, dry eye and conjunctivochalasis (all p < 0.001)
compared to controls [31]. In a study involving 46 patients
with newly diagnosed dry eye and 18 control participants,
tear MMP-9 activity was assessed with an MMP-9 activity
assay in 1 uL of basal tear fluid [32]. The MMP-9 activity
in the control group was 8.39 +/- 4.70 ng/mL and pro-
gressively higher levels of MMP-9 were found in the dry
eye groups with the highest levels corresponding to the
most severe dry eyes clinically [32]. Although this is not a
longitudinal study, it represents correlation of MMP-9levels with clinical disease severity and suggests that it can
be a clinical marker for monitoring patients.
In a study involving treatment of ocular surface dis-
ease, including dry eye, with a therapeutic contact lens,
clinical improvement was observed and at the same
time, tear MMP-9 was found to decrease by day 7 and
further decrease to minimal levels by day 21 [33]. These
types of longitudinal results strengthen the validity of
using the tear MMP-9 assay as a monitoring tool.
InflammaDry (RPSInc, Sarasota, FL, USA) is a rapid
(10 minute) point of care diagnostic test for tear MMP-
9, which gives a positive result if tear MMP-9 exceeds
40 ng/ml. This test can be easily administered by a nurse
or technician. It has a sensitivity of 87% and specificity
of 92% (RPS clinical study: protocol number 09-001, ver-
sion no 2.4) when compared to a combined diagnostic
criteria of dry eye tests (OSDI > =13, Schirmer II <
10 mm, TBUT < 10 sec and staining > =1). This dispos-
able test kit is based on direct sampling of tears from
the inferior fornix using microfiltration and capturing of
MMP-9 between specific monoclonal and polyclonal
antibodies, and does not require specialised equipment.
However, in its current form, the InflammaDry does not
yield the actual MMP-9 concentration [107].
Experimentally, dry eye models in animals have dem-
onstrated the importance of tear MMPs in the induction
of ocular surface damage in dry eyes [34,35] and have
linked these to inflammatory signaling [36], thereby
strengthening the biological basis for clinical use of
MMPs. In experimental dry eye, the raised MMP-9 can
also be detected in the cornea and lacrimal tissues, im-
plying that tear concentrations were not raised purely
due to evaporation [37]. In primary lacrimal gland cul-
tures, pro-MMPs were secreted into the culture medium,
suggesting that the lacrimal gland may be a source of
MMPs [38].
Lipocalin
Lipocalins are a group of extracellular low molecular
weight proteins [108], which use multiple recognition
properties including ligand binding to small hydrophobic
molecules, macro-molecular complexes and binding to
specific cell surface receptors. Tear lipocalin is a major
protein in tears, which binds a variety of lipophilic mole-
cules. It can also bind to macromolecules like lactoferrin
and lysozyme and has a variety of functions in tears, in-
cluding anti-inflammatory activity, binding and release
of lipids [53], regulation of tear viscosity, endonuclease
inactivation of viral DNA and used as a biomarker for
dry eye [109].
In dry eye disease, downregulation of lipophilin-1 and
lipocalin-1 have been found [99]. In fact, the tear lipocalin
was even lower in Sjogren’s syndrome patients compared
to non-Sjogren’s dry eye patients [45]. In a treatment trial
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of dry eye with an increase in the stability of tear film was
found in conjunction with an increase in the tear lipocalin
levels [52]. One risk factor for dry eye is contact lens wear,
and dry eye sufferers also tend to have intolerance to con-
tact lens. Surprisingly, people who are intolerant of con-
tact lens wear demonstrated higher tear lipocalin levels
compared to people who tolerated contact lens [110], sug-
gesting that tear lipocalin alone should not be used for the
diagnosis of dry eye. To the best of our knowledge, there
has been no longitudinal clinical study on levels of lipoca-
lin to-date.
Experimentally, rabbit levels of tear lipocalin were hor-
mone dependent. Ovariectomy in rabbits decreased tear
lipocalin and in contrast, administration of estrogen or
male androgen dihydrotestosterone (DHT) increased the
levels [54]. These studies point out that hormones act
upstream of the production of lipocalin. Interestingly,
addition of exogenous sex steroids resulted in the bind-
ing of these steroids to the tear lipocalin [55]. Since
levels of hormones influence the human dry eye, these
findings provide some evidence linking lipocalins to the
biology of dry eye. Unfortunately, there has been no evi-
dence of tear lipocalin deficiencies in animal models of
dry eye so far.
Interleukines
The interleukins (IL), a group of cytokines that were first
seen to be expressed by leukocytes, have an important
role in the adaptive immune response in that they are re-
quired for the propagation of inflammation [111]. Recently,
a panel of four key inflammatory cytokines (IL-1β, IL-6,
IFN-γ, and TNF-α) were found to be highly reproducible
and reliable when determined in tear samples as little as 4-
10 μL. Standard operating instructions for tear collection,
shipping, storage and processing were recommended [112].
Interleukin 1
Tear ILs, in particular IL-1β has been shown to increase
in aqueous deficiency dry eye [113].
In patients with meibomian gland dysfunction MGD
and those with Sjogren’s syndrome, compared with normal
participants, the concentrations of tear IL-1α and mature
IL-1β were increased, and precursor IL-1β was decreased
[30]. Experimentally, the production of IL-1β in tears has
been linked to inflammation [39,40,59,60,114,115].
Interleukin 6
Tear IL-6 has been found to be elevated in Sjogren’s and
non-Sjogren syndrome dry eye patients [56,57]. In another
study, significant elevation of tear IL-6 has also been ob-
served after 2 weeks of soft contact lens wear. Since the
tears break up time and expression of MUC5AC was also
decreased over this time, the study suggests that increasedtear IL-6 may be an indicator of worsening epithelial and
mucoid function [58]. Interestingly, one of the polymor-
phisms in the IL-6 gene was associated with dry eye dis-
ease [116]. This not only suggests a genetic predisposition
of dry eye for certain populations, but also supports the
use of IL-6 as a marker of dry eye in susceptible people.
Interleukin 17
The tear concentrations of IL-17 in patients with fila-
mentary keratitis, graft versus host disease, autoimmune
keratitis, Sjogren’s syndrome, dry eyes, MGD and Steven
Johnson syndrome were significantly higher than in nor-
mal study participants [117]. This relationship of increased
tear IL-17 was only observed in patients with systemic
autoimmune disease but not in those whose inflammation
is restricted to the eye. Interestingly, serum IL-17 levels
were correlated to fluorescein staining scores, but this
study did not investigate tear IL-17 levels [118].
Tumour necrosis factor-α (TNF-α) and Interferon-γ (IFN-γ)
These are both acute response cytokines that enhance
cellular immune responses [119]. Although tear TNF-α
levels were higher in dry eye than controls [57], there
was no significant correlation between these levels and
the dry eye clinical tests [56]. There was also no differ-
ence between the tear TNF-α levels between Sjogren’s and
non-Sjogren’s dry eye patients [56]. The pro-inflammatory
role of tear TNF-α however, has been verified in experi-
mental models [39,59,60,120,121]. The main drawback in
the use of tear cytokines as markers is that none of these
have been measured longitudinally in clinical studies to-
date.
Tear levels of IFN-γ were elevated in Sjogren’s syn-
drome compared to controls [62]. Similarly, the tear
levels of IFN-γ in cystic fibrosis, a systemic disease asso-
ciated with dry eye, were significantly higher than those
in non-cystic fibrosis controls [63,122]. As in the case of
TNF-α, the pro-inflammatory role of IFN-γ has been
verified in experimental murine dry eye [121,123].
Chemokines and interleukin 8 (CXCL8)
The tear chemokines which have been implicated in dry
eye are CX3CL1 [64], CXCL10 [64], CCL4/MIP-1beta
[124,125], CCL3/MIP-1alpha [57,125,126], CCL5/RANTES
[57], CXCL9, -10, and -11 [127]. The tear levels of CXCL9,
-10 and -11 were 1,148 +/- 1,088, 24,338 +/- 8,706, and
853 +/- 334 pg/mL, in dry eye, and only 272 +/- 269,
18,149 +/- 5,266, and 486 +/- 175 pg/mL in controls re-
spectively [41]. Hyperosmolarity induced the production
of Monocyte chemotactic protein ( MCP)-1 in experimen-
tal (epithelial cell culture) settings, providing a link be-
tween tear chemokines and dry eye pathology [61].
Nevertheless, there is currently no evidence that chemo-
kines are reduced after treatment of dry eye or that
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the detection of dry eye.
The tear levels of proinflammatory cytokine IL-8 was
found to be higher in Sjogren’s syndrome compared to
controls [62]. The levels were also higher in dry eye with
and without MGD compared to normal controls [57]. In
experimental dry eye, IL-8 was also found to be upregu-
lated in the lacrimal gland [36,37]. Ocular pain levels
were correlated to tear IL-8 [64].
Growth factors and wound healing molecules
A number of growth factors are produced by the lacri-
mal gland/ocular surface and may provide trophic effects
for ocular surface epithelium. Intuitively, the levels of
tear growth factors may reflect the extent of trophic sup-
port that is vital for epithelial health [128].
Nerve growth factor and related proteins
It is logical to assess proteins related to nerve endings in
dry eye, since dry eye may result from an interruption of
neural reflex at the afferent nerve endings. The tear
nerve growth factor (NGF) levels were higher in dry eye
patients compared to age- and gender-matched healthy
control participants. In these patients, prednisolone
treatment for 28 days resulted in a decrease in tear NGF
levels, which occurred together with clinical improve-
ment of dry eyes [73]. In another study, tear levels of
NGF were increased in dry eye patients whereas related
peptides: Calcitonic Gene Related Peptide (CGRP) and
Neuropeptide (NP) Y concentrations were decreased
compared to healthy participants. Furthermore, the level
of tear NGF was correlated with clinical severity of dry
eye while CGRP and NPY levels were inversely corre-
lated to these clinical parameters [71]. Tear NGF/total
tear protein ratio was increased in photorefractive kera-
tectomy and laser in situ keratomileusis, and the early
post-operative levels were also correlated with tear func-
tion 6 months later [74]. NGF was elevated in tears of
contact lens wearers with dry eye, and the levels were as-
sociated with a decrease in the nerve plexus density in the
cornea [72], supporting the theory that dry eye results
from a decrease in the afferent part of the lacrimal loop.
The tear concentration of another peptide, substance
P, was also associated with dry eye, and was elevated
after excimer corneal surgery compared to pre-surgical
levels [129].
Is there any evidence of functional mechanisms involv-
ing neural peptides? Experimentally, NGF has been
shown to induce goblet differentiation and increase in
MUC5AC both in human conjunctival epithelial cells ex-
posed to increasing NGF concentrations and confirmed
in primary cultures [75]. Dry eye was induced in rats by
subcutaneous scopolamine treatment and aqueous tear
production, tear clearance, fluorescein corneal staining,and tear break-up time were evaluated. The NGF mimetic
was able to induce an improvement of dry eye test param-
eters and glycoprotein secretion [76]. The use of supple-
mentary NGF for dry eye therapy is however, hard to
justify if the tear level of this protein is already higher than
normal to start with. Further studies are required to deter-
mine why the NGF levels are elevated in dry eye, and per-
haps the use of NGF as a biomarker should be delayed
until substantial longitudinal studies of NGF levels are
available.
Other growth factors
Epidermal growth factor (EGF) is a low molecular
weight polypeptide that acts by binding with high affinity
to the epidermal growth factor receptor (EGFR) on the
cell surface. Stimulation of the intrinsic protein-tyrosine
kinase activity of the receptor ultimately leads to DNA
synthesis and cellular proliferation, differentiation, and
survival [130]. The concentration of tear EGF was signifi-
cantly decreased in non-Sjogren dry eye, Sjogren syn-
drome, and Steven Johnson syndrome patients compared
with controls [68]. On the other hand, higher levels of tear
EGF has been linked to subepithelial fibrosis in dry eye
[69]. In animal models, addition of EGF has been linked to
longer tear break up times and lower fluorescein staining
scores, establishing a functional effect of this growth factor
in the ocular surface [70].
Transforming growth factor (TGF) is a peptide known
to be involved in inflammatory and fibrotic pathways.
TGF-β1 is the prototypic member of the transforming
growth factor superfamily and it elicits diverse cellular
responses like proliferation, induction and regulation de-
pending on cell type, state of differentiation and culture
conditions [131]. In dry eye, tear TGF-β bioactivity, as
assessed by a cell based assay was found to be higher
(9777.5 +/- 10481.9 pg/mL) than those in controls
(4129.3 +/- 1342.9 pg/mL). The level of TGF-β bioactiv-
ity was highest in those with Sjogren syndrome, com-
pared to controls and non-Sjogren dry eye [132]. The
biological role of TGF-β has also been investigated in ex-
perimental dry eye settings [36,37].
Corneal neovascularisation may be observed in very
advanced dry eye and ocular surface failure [133]. Vascu-
lar Endothelial Growth Factor (VEGF) is a signal protein
that stimulates vasculogenesis and angiogenesis, cell sur-
vival, migration and differentiation. When VEGF is over-
expressed, it can contribute to neovascularisation [134].
Tear VEGF levels have been found to be raised in dry
eye compared to controls in a study comparing evapora-
tive dry eye to normal subjects. Epidermal growth factor
(EGF), fractalkine/CX3CL1, IL-1-receptor antagonist
(RA), IL-8/CXCL8, interferon inducible protein (IP)-10/
CXCL10 were found elevated along with VEGF in 94%–
100% of samples [64]. Despite the promise of using
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longitudinal study that evaluated the tear levels of these
proteins.
Miscellaneous tear proteins and future directions
There are some interesting proteins that have not been
evaluated as thoroughly as those mentioned above, but
future research will show their usefulness or otherwise
in clinical scenarios. The phospholipase (PL)A2-IIa con-
centration was found to be lower in patients with ocular
rosacea (31.0+/-18.4 μg/ml) and in patients who had dry
eye (25.8+/-15.1 μg/ml), compared to normal controls
[135]. The activity of serum PLA2-IIa was significantly
increased in tears from dry eye diseased patients com-
pared to those from normal subjects. In addition, serum
PLA2-IIa stimulated the production of prostaglandin E
(2) in ocular surface epithelial cell cultures, linking this
tear protein to inflammation [135]. We have previously
reported the involvement of other proteins (e.g., prolactin-
induced protein, enolase and orosomucoid) in dry eye [5].
These have not been as well characterized as the other tear
proteins above. Lacritin is a tear protein that is reduced in
dry eye. Because it protects against cells from stress, re-
placement of lacritin has been advocated as a form of
treatment in dry eye. Furthermore, an ELISA assay has
been developed to quantify lacritin levels [136].
Specific molecules such as B cell activating factor may
indicate severity of inflammation in Sjogren syndrome
[137]. Similarly, tear aquaporin 5 was increased in the
tears of Sjogren syndrome, indicating the level of lacri-
mal damage [68]. Increased levels of anti-Ro or anti-
La may also be detected in tears of Sjogren syndrome
[138], although the role of this assay is currently not
clear. The tear levels of pro-apoptotic proteins such as
sFas have been measured in patients with dry eye asso-
ciated with cystic fibrosis [139], and it is possible that
subject to further studies, this marker may have some
clinical application.
In addition, the tear levels of albumin may also serve
as a marker of inflammation. In one study the levels of
albumin were found to be increased in glaucoma pa-
tients with dry eye [44]. Some proteins are poorly under-
stood and there is no clear strategy that can ‘restore’ this
to normal. For example, we found the scaffolding pro-
tein 14-3-3 to be uniquely upregulated in glaucoma pa-
tients with dry eye who used chronic medications but
not in other dry eye patients [14]. It may be possible to
use such markers to monitor these patients’ progress
even if the biological link is unclear, but more research
such as longitudinal studies would be required to ad-
dress this.
A great difficulty in diagnostic science is the wide vari-
ation of techniques used in analysis. The differences in
techniques can result in the variation of the ‘normal’range of specific tear proteins [140]. The extent of vari-
ation of tear proteins during processes such as fasting
should also be further investigated [141]. Particular care
should be paid to the conditions during tear collection:
close eye tears and open eye tears differ in the fibronec-
tin concentrations [23]. It may be necessary for an inter-
national panel to set up universal standards for the
testing of specific tear proteins, or testing of patients for
specific purposes, such as for the selection of treatment
modality in dry eye.
Much remains to be done in terms of developing clinic
based assays and ascertaining their reliability. Technolo-
gies that rapidly produce results and take up minimal
amount of space are highly promising, such as the one
using a microfluidics chip mentioned above [89].
Although this review focuses on proteins, tear lipids
mediators in the tear may also have a major role in in-
flammation, and are potentially useful biomarkers. For
example, the omega-3 fatty acid metabolic pathways pro-
duce both pro-inflammatory lipids (leukotrienes) as well
as anti-inflammatory lipids (e.g., the 18R-, 17R- and 18S-
resolvins). The resolvins (Rv)E1, neuroprotectin D1 and
RvD1 dampen a range of immune responses including
T cell responses, cytokine production, and endothelial
adhesion. In fact, the RvE1 analog Rx-10045 has com-
pleted phase II testing for treatment of dry eye (clini-
caltrials.gov NCT01675570). Assuming that diagnostic
technology of lipid detection overcomes certain prac-
tical obstacles, tear lipids may be useful biomarkers for
guiding therapies.
Conclusions
We propose that when a patient presents with dry eye
symptoms, the history and the clinical examination will
alert to any systemic diseases that may be linked to dry
eye, for example, rheumatoid arthritis or Sjogren’s syn-
drome. In recalcitrant cases of dry eye, tear proteins may
be useful for selection of treatment or following up the
patient for response to treatment. For example, in-
creased tear MMPs may suggest the more prolonged use
of MMP inhibitors like the doxycyclines. In conclusion,
clinicians are reminded that tear protein science is an
evolving area of research and with increasing knowledge
on the pathogenesis of specific types of dry eyes, more
appropriate biomarkers may replace these mentioned in
this article.
Retrieval of articles
The NCBI Pubmed database was searched for the key-
words “Tear Proteins” and “Dry eye” in any field. This
yielded 471 articles, and these have been manually cu-
rated to 131 relevant articles by excluding those that do
not support the criteria in Table 1. Seven articles were
added to introduce the proteins in each section.
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